The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
AbstractImatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have been clearly proven...
- Abstract views: 1006
- FULL TEXT: 152
Copyright (c) 2011 Camillo Porta, Federica Tagliani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.